The European Medicines Agency (EMA) has published a notice to sponsors on the validation and qualification of computerised systems used in clinical trials, outlining expectations for ensuring data integrity and regulatory compliance. The document, released on 4 May 2026, is addressed to pharmaceutical companies, contract research organisations, and other sponsors conducting clinical trials in the European Economic Area.
The notice is a guidance document, not a binding regulation, but it sets out the Agency's interpretation of existing legal requirements under the Clinical Trials Regulation (EU) No 536/2014 and Good Clinical Practice (GCP) guidelines. It emphasises that computerised systems used for trial data collection, processing, and storage must be validated to ensure accuracy, reliability, and consistent performance. The document also addresses qualification of the system's hardware and software environment, including installation, operational, and performance qualification.
Policy orientations and trade-offs The notice strikes a balance between ensuring data quality and avoiding disproportionate burden on sponsors. On one hand, it requires rigorous validation and documentation, which can increase costs and development timelines for sponsors, especially smaller firms. On the other hand, it provides flexibility by allowing risk-based approaches and referencing international standards (e.g., ISO 27001) to avoid duplication. The document also clarifies that existing validated systems may be used if they meet the requirements, reducing the need for re-validation.
Impact on stakeholders - Sponsors (pharma and biotech companies): They face moderate additional compliance costs for validating new or modified systems, but benefit from clearer regulatory expectations, reducing uncertainty and potential inspection findings. - Contract research organisations (CROs): They must ensure their own systems comply, potentially requiring investment in validation processes, but may gain a competitive advantage if they already meet the standards. - National competent authorities: They gain a harmonised reference for inspections, facilitating consistent enforcement across member states. - Patients and trial participants: Indirectly benefit from improved data integrity and reliability of trial results, enhancing trust in clinical research.
Expected institutional follow-up The notice is effective immediately. EMA may issue further Q&A documents or update the guidance as experience accumulates. Sponsors are expected to implement the principles in ongoing and new trials. The Agency may also incorporate the notice into future GCP inspection procedures.
← Atlas › News › Health & Lifestyle